Scientists engineered mesenchymal stromal cells (MSCs) with synthetic mRNA to produce an allogeneic cell therapy dubbed DC‑25 that enhances immune-modulatory signals and resists host rejection. Preclinical data show improved functional markers versus unmodified MSCs and support an allogeneic manufacturing pathway. The work frames mRNA as a transient, tunable engineering tool to load off‑the‑shelf cells with therapeutic payloads while avoiding genomic modification. Authors discuss implications for scaling immunotherapies and reducing reliance on patient-derived autologous products. Clarification: MSCs are multipotent stromal cells used in cell therapy for immune modulation; mRNA engineering delivers transient protein expression without permanent genetic edits.